An IND filing for acute MS relapses is planned for Q4 2026, setting up a new clinical trial pathway beyond optic neuritis.
Additional updates on the program are slated for a virtual R&D Day in Q4 2026.
FDA feedback supports Privosegtor expansion
Oculis received FDA pre-IND feedback backing its Privosegtor program for acute multiple sclerosis relapses.
Results from the earlier Phase 2 ACUITY study have already been presented, showing neuroprotective benefits in optic neuritis without detailing metrics.
The FDA supported using existing Privosegtor data for a new IND, lowering development friction for the expansion into MS relapses.
OCS•
